{
    "clinical_study": {
        "@rank": "72251", 
        "acronym": "ATD", 
        "arm_group": [
            {
                "arm_group_label": "0.2 mg triptorelin", 
                "arm_group_type": "Active Comparator", 
                "description": "0.2 mg triptorelin compared with 0.1 mg triptorelin and 0.4 mg triptorelin"
            }, 
            {
                "arm_group_label": "0.1 mg triptorelin", 
                "arm_group_type": "Active Comparator", 
                "description": "0.1 mg triptorelin compared with 0.2 mg triptorelin and 0.4 mg triptorelin"
            }, 
            {
                "arm_group_label": "0.4 mg triptorelin", 
                "arm_group_type": "Active Comparator", 
                "description": "0.4 mg triptorelin compared with 0.1 mg triptorelin and 0.2 mg triptorelin"
            }
        ], 
        "brief_summary": {
            "textblock": "The present study aims to investigate whether the  dosage of the GnRH agonist used for\n      triggering final oocyte maturation affects the maturity of the oocytes retrieved in high\n      risk for OHSS patients undergoing ovarian stimulation for IVF using GnRH antagonists and\n      recombinant FSH.\n\n      Three different doses of GnRH agonist (0.1mg, 0.2mg or 0.4 mg) will be used randomly to\n      trigger final oocyte maturation. The primary outcome measure will be the percentage of\n      mature oocytes retrieved.\n\n      Secondary outcomes will include: number of oocytes retrieved, oocyte recovery rate (number\n      of oocytes retrieved/ number of follicles >11mm in diameter on the day of triggering),\n      fertilization rates and OHSS occurrence.\n\n      Serum LH, FSH, E2, PRG levels will be assessed at 8-36 hours following agonist\n      administration and on days 3-4-7-10 after triggering final oocyte maturation."
        }, 
        "brief_title": "Evaluation of the Optimal Dose of GnRH Agonist for Triggering Final Oocyte Maturation in High Risk OHSS Patients", 
        "completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Subfertility", 
        "condition_browse": {
            "mesh_term": "Infertility"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria: Patients undergoing ovarian stimulation for IVF using GnRH antagonist\n        protocol\n\n          -  Age < 40 years\n\n          -  Anticipated high ovarian response\n\n        Exclusion Criteria:\n\n          -  Endometriosis > than grade II\n\n          -  One ovary"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "40 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "90", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01973842", 
            "org_study_id": "Agonist triggering dose"
        }, 
        "intervention": [
            {
                "arm_group_label": "0.1 mg triptorelin", 
                "intervention_name": "0.1 mg triptorelin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "0.2 mg triptorelin", 
                "intervention_name": "0.2 mg triptorelin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "0.4 mg triptorelin", 
                "intervention_name": "0.4 mg triptorelin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Triptorelin", 
                "Deslorelin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "GnRH agonist", 
            "OHSS", 
            "Triggering final oocyte maturation"
        ], 
        "lastchanged_date": "February 5, 2014", 
        "location": [
            {
                "contact": {
                    "email": "tlainas@otenet.gr", 
                    "last_name": "Trifon Lainas, MD, PhD"
                }, 
                "facility": {
                    "address": {
                        "city": "Athens", 
                        "country": "Greece"
                    }, 
                    "name": "Eugonia IVF Unit"
                }, 
                "investigator": {
                    "last_name": "Trifon Lainas, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "stratis.kolibianakis@gmail.com", 
                    "last_name": "Efstratios Kolibianakis, MD, MSc, PhD"
                }, 
                "facility": {
                    "address": {
                        "city": "Thessaloniki", 
                        "country": "Greece"
                    }, 
                    "name": "Unit of Human Reproduction, 1st Dept of Obstetrics and Gynaecology, Medical School, Aristotle University of Thessaloniki"
                }, 
                "investigator": [
                    {
                        "last_name": "Efstratios Kolibianakis, MD, MSc, PhD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Georgios Lainas, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Greece"
        }, 
        "number_of_arms": "3", 
        "official_title": "Evaluation of the Optimal Dose of GnRH Agonist for Triggering Final Oocyte Maturation in High Risk OHSS Patients Undergoing Ovarian Stimulation for IVF With GnRH Antagonists and Recombinant FSH.", 
        "overall_contact": {
            "email": "stratis.kolibianakis@gmail.com", 
            "last_name": "Efstratios Kolilbianakis, MD, MSc, PhD"
        }, 
        "overall_contact_backup": {
            "email": "g.lainas@yahoo.co.uk", 
            "last_name": "Georgios Lainas, MD"
        }, 
        "overall_official": {
            "affiliation": "Unit of Human Reproduction, 1st Dept of Obstetrics and Gynaecology, Medical School, Aristotle University of Thessaloniki Thessaloniki, Greece", 
            "last_name": "Efstratios Kolibianakis, MD, MSc, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Greece: Ministry of Health and Welfare", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Percentage of mature oocytes retrieved following oocyte retrieval", 
            "measure": "Percentage of mature oocytes retrieved", 
            "safety_issue": "No", 
            "time_frame": "36 hours post GnRH agonst administration"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01973842"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Aristotle University Of Thessaloniki", 
            "investigator_full_name": "E.M. Kolibianakis", 
            "investigator_title": "Ass Professor in Obstetrics - Gynecology and Assisted Reproduction", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "total number of oocytes retrieved", 
                "safety_issue": "No", 
                "time_frame": "36 hours post GnRH agonist administration"
            }, 
            {
                "measure": "oocyte recovery rate", 
                "safety_issue": "No", 
                "time_frame": "36 hours post GnRH agonist administration"
            }, 
            {
                "measure": "Fertilization rate", 
                "safety_issue": "No", 
                "time_frame": "Day 1 post oocyte retrieval"
            }, 
            {
                "measure": "Serum LH, FSH, E2, PRG levels", 
                "safety_issue": "No", 
                "time_frame": "8-36 hours post triggering and on days 3-4-7-10 after GnRH agonist administration"
            }, 
            {
                "measure": "Duration of luteal phase", 
                "safety_issue": "No", 
                "time_frame": "16 days"
            }, 
            {
                "description": "Occurrence of ovarian hyperstimulation syndrome", 
                "measure": "OHSS occurrence", 
                "safety_issue": "Yes", 
                "time_frame": "16 days post triggering"
            }
        ], 
        "source": "Aristotle University Of Thessaloniki", 
        "sponsors": {
            "collaborator": {
                "agency": "Eugonia IVF Unit", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Aristotle University Of Thessaloniki", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}